Latest News
CRANBURY, N.J., Oct. 15, 2026 - Accutar Biotechnology today announced the achievement of a preclinical development milestone in its collaboration and licensing agreement with Cytokinetics, Incorporated to discover and develop novel targeted protein degraders to treat muscle-related diseases.
“We’re excited to have reached this first milestone in our research collaboration with Cytokinetics, a leading muscle-focused company whose deep disease biology expertise and commitment to innovation align well with our vision of transforming drug discovery through AI,” said Jie Fan, Ph.D.,...
New Jersey | July 10 2026
HEC Pharm has formally entered into an agreement with Accutar, a leading global AI-enabled drug discovery company, to form a new company ("NewCo") and jointly develop an innovative drug pipeline based on Regulated Induced Proximity Targeting Chimera (RIPTAC) technology. The pipeline's lead indication will be metastatic castration-resistant prostate cancer (mCRPC), a disease area with substantial unmet medical need...
Results from a Phase 1 clinical study of AC699, Accutar Biotechnology’s investigational oral estrogen receptor (ER) degrader, were published in Nature Communications on December 17, 2025. The study assessed safety and preliminary antitumor activity in 37 patients with heavily pretreated ER-positive/HER2-negative advanced or metastatic breast cancer.
All adverse events considered related to AC699 were mild or moderate (Grade 1 or 2), with no dose...
CRANBURY, N.J.--(BUSINESS WIRE)--Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced today that the US Food and Drug Administration (FDA) has granted the investigation of AC699 a Fast Track designation for the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with disease progression on...
– Differentiated Mechanism of Action of a Chimeric Degrader as Compared to Fulvestrant and Novel SERDs –
– Treatment with AC699 Monotherapy Resulted in 21% ORR for All Evaluable Patients, and 50% for Those Who Had an ESR1 Mutation –
– Favorable Safety and Tolerability Profile at All Doses with No DLTs or ≥ Grade 3 Adverse Events Related to AC699...